JAZZ Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 47% planned / 53% discretionary
Largest single sale: $6.8M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| GALA RENEE D | President & CEO | Sell 10b5-1 | 2,000 | $243.03 | $486.1K | 143,394 −1.4% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 6,000 | $250.13 | $1.5M | 351,875 −1.7% of holding | |
| Iannone Robert 6 fills | EVP, Global Head of R&D & CMO | Sell 10b5-1 | 76,921 | $249.70 | $19.2M | 124,420 −38.2% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 6,000 | $252.98 | $1.5M | 360,682 −1.6% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 6,000 | $240.47 | $1.4M | 366,682 −1.6% of holding | |
| Smith Mark Douglas | Director | Sell 10b5-1 | 1,157 | $230.55 | $266.7K | 9,680 −10.7% of holding | |
| Patil Neena M | EVP & Chief Legal Officer | Sell 10b5-1 | 1,200 | $231.83 | $278.2K | 51,549 −2.3% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 6,000 | $235.12 | $1.4M | 372,682 −1.6% of holding | |
| Pearce Samantha | EVP, Chief Commercial Officer | Sell | 6,907 | $235.41 | $1.6M | 50,272 −12.1% of holding | |
| Patil Neena M | EVP & Chief Legal Officer | Sell 10b5-1 | 1,192 | $236.97 | $282.5K | 52,626 −2.2% of holding | |
| Winningham Rick E | Director | Sell | 2,741 | $241.57 | $662.1K | 9,567 −22.3% of holding | |
| McSharry Heather Ann | Director | Sell | 2,000 | $241.00 | $482.0K | 18,449 −9.8% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 6,000 | $203.33 | $1.2M | 378,682 −1.6% of holding | |
| COZADD BRUCE C 3 fills | Director | Sell 10b5-1 | 6,000 | $190.50 | $1.1M | 386,998 −1.5% of holding | |
| Carr Patricia | SVP, Chief Accounting Officer | Sell | 1,287 | $182.94 | $235.4K | 6,512 −16.5% of holding | |
| COZADD BRUCE C 3 fills | Director | Sell 10b5-1 | 6,000 | $186.44 | $1.1M | 408,637 −1.4% of holding | |
| RIEDEL NORBERT G | Director | Sell | 3,415 | $192.00 | $655.7K | 7,024 −32.7% of holding | |
| Carr Patricia | SVP, Chief Accounting Officer | Sell | 1,117 | $190.91 | $213.2K | 9,235 −10.8% of holding | |
| Patil Neena M 11 fills | EVP & Chief Legal Officer | Sell | 55,600 | $191.56 | $10.7M | 68,391 −44.8% of holding | |
| Henderson Mary Elizabeth | SVP, Technical Operations | Sell | 5,343 | $194.49 | $1.0M | 28,728 −15.7% of holding | |
| Carr Patricia | SVP, Chief Accounting Officer | Sell | 1,253 | $194.11 | $243.2K | 10,352 −10.8% of holding | |
| Henderson Mary Elizabeth | SVP, Technical Operations | Sell | 2,238 | $169.51 | $379.4K | 19,508 −10.3% of holding | |
| Carr Patricia 2 fills | SVP, Chief Accounting Officer | Sell | 4,660 | $171.20 | $797.8K | 7,012 −39.9% of holding | |
| COZADD BRUCE C 4 fills | Director | Sell | 77,500 | $177.81 | $13.8M | 440,345 −15% of holding | |
| McSharry Heather Ann | Director | Sell | 3,415 | $177.78 | $607.1K | 20,449 −14.3% of holding | |
| COZADD BRUCE C 4 fills | Director | Sell | 18,000 | $181.09 | $3.3M | 405,442 −4.3% of holding | |
| Winningham Rick E | Director | Sell | 5,500 | $180.86 | $994.7K | 8,893 −38.2% of holding | |
| Carr Patricia 2 fills | SVP, Chief Accounting Officer | Sell | 5,319 | $182.06 | $968.4K | 7,012 −43.1% of holding | |
| Iannone Robert | EVP, Global Head of R&D & CMO | Sell 10b5-1 | 7,159 | $168.26 | $1.2M | 72,628 −9% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 3,500 | $140.00 | $490.0K | 408,826 −0.8% of holding | |
| COZADD BRUCE C | Director | Sell 10b5-1 | 2,000 | $131.78 | $263.6K | 412,326 −0.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.